The relationship between the KRAS expression level and PARPi efficacy in this study may provide a new direction for further preclinical trials of PARPi usage in such rare ovarian cancers and other malignancies with predominant KRAS mutations, such as colon cancer [37,38]. The gene discussed is KRAS; the disease is colonic neoplasm.